Home  >>  News  >>  Biocon Biologics Gets USFDA Nod for Cancer Drug Jobevne
Biocon Biologics Gets USFDA Nod for Cancer Drug Jobevne

Biocon Biologics Gets USFDA Nod for Cancer Drug Jobevne

Biocon Biologics has achieved a significant milestone by receiving USFDA approval for Jobevne, a biosimilar to the cancer drug Avastin. This biosimilar is designed to treat various types of cancer by inhibiting vascular endothelial growth factor (VEGF), which plays a crucial role in tumor blood supply. With this approval, Biocon is expanding its oncology offerings in the US, complementing its existing products like OGIVRI and FULPHILA. Additionally, the company plans to issue commercial papers worth up to Rs 600 crore. Despite recent share price fluctuations, Biocon's market presence remains strong.

Trending News